Literature DB >> 1312868

Antisense inhibition of oncogene expression.

L Neckers1, L Whitesell, A Rosolen, D A Geselowitz.   

Abstract

To understand the role of individual genes in regulating biological processes, one must be able to interfere specifically with either their expression or function. While monoclonal antibodies have proven very useful in studying cell surface proteins, the specific inhibition of intracellular proteins in viable cells is a much more difficult problem. The goal of antisense technology is to develop small oligonucleotides, plasmids, or retroviral vectors which can be readily introduced into living cells in order to inhibit specific gene expression. In this review, we briefly describe the principles of antisense usage, including problems of cellular uptake and intracellular distribution, mechanism of antisense action, and the properties of various oligonucleotide derivatives. In addition we present several examples of the biological effects of antisense administration used to study the role of specific genes in the regulation of cell growth and differentiation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1312868

Source DB:  PubMed          Journal:  Crit Rev Oncog        ISSN: 0893-9675


  19 in total

1.  Inhibitory effects of EGFR antisense oligodeox ynucleotide in human colorectal cancer cell line.

Authors:  Yong He; Jun Zhou; Jin-Sheng Wu; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2000-10       Impact factor: 5.742

Review 2.  Antisense approaches to the gene therapy of cancer--'Recnac'.

Authors:  I Gibson
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Antisense inhibition of the PTI-1 oncogene reverses cancer phenotypes.

Authors:  Z Su; N I Goldstein; P B Fisher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

4.  Selection and characterization of RNAs that relieve transcriptional interference in Escherichia coli.

Authors:  G A Soukup; J J Maher
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

5.  Transforming growth factor-alpha antisense vectors can inhibit glioma cell growth.

Authors:  P Tang; S A Jasser; J C Sung; Y Shi; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

6.  Differential distribution of oligodeoxynucleotides in developing organs with epithelial-mesenchymal interactions.

Authors:  U W Rothenpieler; G R Dressler
Journal:  Nucleic Acids Res       Date:  1993-10-25       Impact factor: 16.971

7.  Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.

Authors:  Y Ohta; H Kijima; T Ohkawa; M Kashani-Sabet; K J Scanlon
Journal:  Nucleic Acids Res       Date:  1996-03-01       Impact factor: 16.971

8.  Stability, clearance, and disposition of intraventricularly administered oligodeoxynucleotides: implications for therapeutic application within the central nervous system.

Authors:  L Whitesell; D Geselowitz; C Chavany; B Fahmy; S Walbridge; J R Alger; L M Neckers
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

9.  Folate-mediated targeting of antisense oligodeoxynucleotides to ovarian cancer cells.

Authors:  S Li; H M Deshmukh; L Huang
Journal:  Pharm Res       Date:  1998-10       Impact factor: 4.200

10.  Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy.

Authors:  G S Robinson; E A Pierce; S L Rook; E Foley; R Webb; L E Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.